2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
John Cole, MD, chairman, Community Oncology Practices, South Shore, Ochsner Medical Center, Ochsner Health, discusses the next steps with tucatinib (Tukysa) in HER2-positive breast cancer.
The phase 3 HER2CLIMB-02 trial (NCT03975647) is currently recruiting patients with advanced or metastatic HER2-positive breast cancer to evaluate the efficacy of ado-trastuzumab emtansine (T-DM1; Kadcyla) plus tucatinib vs T-DM1 alone. However, the results of this study may be difficult to integrate into clinical practice given the positive results of the phase 3 DESTINY-Breast03 trial (NCT03529110), which were presented during the 2021 San Antonio Breast Cancer Symposium. The findings demonstrated that fam-trastuzumab deruxtecan-nxki (Enhertu) elicited superior efficacy vs T-DM1 as second-line therapy for patients with HER2-positive metastatic breast cancer.
Knowledge of tucatinib remains limited as the agent is relatively new, so significant research is needed to determine whether tucatinib-based combinations will be more effective vs single-agent tucatinib, Cole explains. Moreover, it will be important to evaluate whether the combinations yield acceptable toxicities and efficacy that outweighs sequential therapy, Cole concludes.
Related Content: